1. Home
  2. FPI vs DSGN Comparison

FPI vs DSGN Comparison

Compare FPI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmland Partners Inc.

FPI

Farmland Partners Inc.

HOLD

Current Price

$10.58

Market Cap

435.7M

Sector

Real Estate

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.33

Market Cap

504.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FPI
DSGN
Founded
2013
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
435.7M
504.7M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
FPI
DSGN
Price
$10.58
$9.33
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
517.0K
498.7K
Earning Date
02-18-2026
11-05-2025
Dividend Yield
2.27%
N/A
EPS Growth
296.76
N/A
EPS
1.27
N/A
Revenue
$52,990,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.37
$2.60
52 Week High
$12.87
$10.31

Technical Indicators

Market Signals
Indicator
FPI
DSGN
Relative Strength Index (RSI) 69.99 51.98
Support Level $10.05 $8.82
Resistance Level $9.73 $10.01
Average True Range (ATR) 0.19 0.65
MACD 0.08 -0.04
Stochastic Oscillator 99.61 62.37

Price Performance

Historical Comparison
FPI
DSGN

About FPI Farmland Partners Inc.

Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: